Corcept Therapeutics Incorporated (NASDAQ: CORT)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company, is focused on engaging in the development of GR-II antagonist drugs for the treatment of severe psychiatric and metabolic diseases. CORLUX, the company’s lead product, is currently in Phase 3 clinical trials for the treatment of the psychotic features of psychotic depression and Cushing’s Syndrome. Additionally, Corcept is preparing for clinical trials to evaluate CORLUX for the mitigation of weight gain induced by antipsychotic medications as well as continuing the development of its proprietary, selective GR-II antagonists. For further information, visit the Company’s web site at www.corcept.com.